Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.

Data were analyzed from 2 prospective, double-blind, placebo-controlled trials of escitalopram in obsessive-compulsive disorder (OCD) to characterize the baseline levels of functional disability and impairment in health-related quality of life (HRQoL) and to assess the relationship between treatment outcomes (response or relapse) and disability or HRQoL. Data from a 24-week, placebo-controlled, fixed-dose trial (N = 466) of escitalopram (10-20 mg/d) or paroxetine (40 mg/d) and from a 40-week, flexible-dose (escitalopram 10-20 mg/d), placebo-controlled relapse-prevention trial (N = 468) were analyzed. Obsessive-compulsive disorder symptoms (DSM-IV criteria) were assessed using the Yale-Brown Obsessive Compulsive Scale (YBOCS), functioning was assessed using the Sheehan Disability Scale (SDS), and HRQoL was assessed using the Medical Outcomes Study Short Form (SF-36). Baseline data were pooled for patients across both studies. For patients in the fixed-dose study, SDS and SF-36 scores were compared across treatment groups and for responders versus nonresponders. In the relapse-prevention trial, SDS and SF-36 scores were compared for relapsed versus nonrelapsed patients. Patients with more severe baseline symptoms (YBOCS > or = 27) reported significantly greater impairment on the SDS (P < .001) and SF-36 (except for bodily pain). Patients receiving escitalopram or paroxetine reported significant improvements on most SF-36 dimensions and on the SDS compared to placebo; however, improvements in work-related functioning were seen earlier for patients receiving escitalopram (20 mg/d). At the study endpoints, SDS and SF-36 scores were significantly better for patients who were responders (versus nonresponders) and for patients who did not relapse (versus relapsers). Obsessive-compulsive disorder is associated with significant impairment in functioning and HRQoL. Significant differences in disability and HRQoL between responders and nonresponders or relapsers and nonrelapsers suggest a relationship between symptomatic and functional outcomes. lundbecktrials.com Identifiers: 10205 and 10193.

Hollander E ，Stein DJ ，Fineberg NA ，Marteau F ，Legault M ... -  《-》

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A 《-》

Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.

Stein DJ ，Andersen EW ，Overo KF 《REVISTA BRASILEIRA DE PSIQUIATRIA》

Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.

Stein DJ ，Andersen EW ，Tonnoir B ，Fineberg N ... -  《-》

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.

Hollander E ，Allen A ，Steiner M ，Wheadon DE ，Oakes R ，Burnham DB ，Paroxetine OCD Study Group ... -  《JOURNAL OF CLINICAL PSYCHIATRY》